Adaptive Biotechnologies Stock Price, News & Analysis

Adaptive Biotechnologies has received FDA clearance for its clonoSEQ® Assay, the first assay approved for monitoring minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) patients using blood samples. This significant advancement expands previous FDA approvals for MRD detection in bone marrow for multiple myeloma and B-cell acute lymphoblastic leukemia (ALL). The assay's sensitivity allows for early detection of cancer recurrence, enhancing patient management. Medicare coverage supports access to this innovative testing method, crucial for the mostly elderly CLL patient population.

Adaptive Biotechnologies (Nasdaq: ADPT) has launched immunoSEQ T-MAP COVID, a proprietary product to measure and track COVID-19 specific T-cell responses in clinical trials. Utilizing data from over 1,000 COVID-19 patients, the platform highlights that T-cell responses can persist for over 90 days post-infection, providing critical insight into immunity. The product leverages the ImmuneCODE database, developed in partnership with Microsoft, to support vaccine trials and therapeutic development, and aims to enhance next-generation vaccine design.

Adaptive Biotechnologies Corp. (Nasdaq: ADPT) announced the launch of ImmuneSense Lyme™, a research study aimed at improving early detection of Lyme disease, which often goes misdiagnosed. The study targets approximately 1,000 participants in areas with high Lyme incidence. Early detection is crucial as current tests have a high false negative rate of 60-70%. The initiative employs AI to analyze immune responses, especially T cells, to enhance diagnostic accuracy. Participants can enroll via local sites or tele-health, fostering broader accessibility.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced the pricing of an underwritten public offering of 8,000,000 shares at $40.00 each, raising gross proceeds of $240 million. The offering includes 6,000,000 shares from Adaptive and 2,000,000 from a selling shareholder, with an option for underwriters to purchase an additional 1,200,000 shares. Proceeds will primarily fund TCR-Antigen Map activities, scale marketing for immunoSEQ Dx products, and support R&D efforts. The transaction is expected to close on July 20, 2020.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced a proposed underwritten public offering of 8,000,000 shares of its common stock, with 6,000,000 shares from Adaptive and 2,000,000 from a selling shareholder. The company expects to grant underwriters a 30-day option for 1,200,000 additional shares. Net proceeds will primarily fund investments in TCR-Antigen Map activities and expand marketing for immunoSEQ Dx products, while also supporting R&D initiatives. The offering is subject to market conditions, and Adaptive will not receive proceeds from the selling shareholder's shares.

Adaptive Biotechnologies (Nasdaq: ADPT) will announce its financial results for Q2 2020 on August 10, 2020, after market close. The company's conference call will start at 1:30 p.m. PT (4:30 p.m. ET). Adaptive aims to leverage the adaptive immune system to develop clinical products for diagnosing and treating diseases, including cancer and autoimmune conditions. They have two commercial products and a robust clinical pipeline to drive future growth.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced participation in two upcoming investor virtual conferences. The events include a Fireside Chat at the William Blair Virtual Growth Stock Conference on June 9 at 10 a.m. PT and a Fireside Chat at the Goldman Sachs Virtual Healthcare Conference on June 11 at 1:40 p.m. PT. Interested parties can access the live and archived webcasts on the company's website. Adaptive Biotechnologies focuses on developing clinical products utilizing the adaptive immune system for diagnosing and treating diseases.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) has announced its participation in several upcoming investor virtual conferences. Key events include the Jefferies Virtual Healthcare Conference on June 4 at 10 a.m. PT, and the William Blair Virtual Growth Stock Conference and Goldman Sachs Virtual Healthcare Conference, both on June 11, at 10 a.m. PT and 12 p.m. PT, respectively. Interested participants can access live and archived webcasts on the company’s website. Adaptive Biotechnologies focuses on using the adaptive immune system to develop diagnostic and therapeutic products for various diseases.

Adaptive Biotechnologies (Nasdaq: ADPT) reported strong financial results for Q1 2020, with revenues reaching $20.9 million, a 65% increase year-over-year. Notably, clinical tests for clonoSEQ surged 75% to 3,518 tests. The company expanded its partnership with Microsoft to tackle COVID-19 diagnostics and formed a strategic alliance with Amgen for therapeutic antibody development. However, operating expenses rose to $55.5 million, leading to a net loss of $31.4 million. Due to COVID-19 uncertainty, the company withdrew its annual revenue guidance for 2020.